Literature DB >> 16438939

Searching for a new anti-HCV therapy: synthesis and properties of tropolone derivatives.

Anna M Boguszewska-Chachulska1, Mariusz Krawczyk, Andzelika Najda, Katarzyna Kopańska, Anna Stankiewicz-Drogoń, Włodzimierz Zagórski-Ostoja, Maria Bretner.   

Abstract

Hepatitis C virus (HCV) is considered one of the most dangerous pathogens since about 3% of the world population is HCV-infected and the virus is a major cause of hepatitis, cirrhosis, and liver carcinoma. A need for a more efficient therapy prompted us to investigate new class of compounds, such as tropolone derivatives that possess antiviral, antibacterial, and antifungal activities. To synthesize bromo- and morpholinomethyl-analogues of tropolone, the previously reported methods were modified. The influence of new derivatives on the activity of the helicase and NTP-ase of HCV was investigated. The most potent inhibitory effect in the fluorometric helicase assay was exerted by 3,7-dibromo-5-morpholinomethyltropolone, for which the IC50 value was at low micromolar range. All the morpholino-derivatives had inhibitory activities higher than those of the non-modified analogues. Low toxicity in a yeast-based toxicity assay indicates that these compounds could be further modified to develop potent inhibitors of the HCV helicase and of viral replication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16438939     DOI: 10.1016/j.bbrc.2006.01.015

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H.

Authors:  Elena Lomonosova; Jil Daw; Aswin K Garimallaprabhakaran; Nana B Agyemang; Yashkumar Ashani; Ryan P Murelli; John E Tavis
Journal:  Antiviral Res       Date:  2017-06-17       Impact factor: 5.970

Review 2.  Step-by-step progress toward understanding the hepatitis C virus RNA helicase.

Authors:  David N Frick
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

3.  Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.

Authors:  Craig A Belon; David N Frick
Journal:  Future Virol       Date:  2009-05-01       Impact factor: 1.831

4.  Monitoring helicase activity with molecular beacons.

Authors:  Craig A Belon; David N Frick
Journal:  Biotechniques       Date:  2008-10       Impact factor: 1.993

5.  NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system.

Authors:  Agnieszka Gozdek; Igor Zhukov; Agnieszka Polkowska; Jaroslaw Poznanski; Anna Stankiewicz-Drogon; Jerzy M Pawlowicz; Wlodzimierz Zagórski-Ostoja; Peter Borowski; Anna M Boguszewska-Chachulska
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

6.  Dicarbon-yl[2-hydr-oxy-3,5,7-tris-(mor-pho-linomethyl)cyclo-hepta-2,4,6-trien-onato(1-)-κO,O]rhodium(I).

Authors:  Tania N Hill; G Steyl
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-11-20

7.  Antiviral therapy for hepatitis C virus: beyond the standard of care.

Authors:  Leen Delang; Lotte Coelmont; Johan Neyts
Journal:  Viruses       Date:  2010-03-29       Impact factor: 5.818

8.  New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.

Authors:  Josep Quer; Maria Buti; Maria Cubero; Jaume Guardia; Rafael Esteban; Juan Ignacio Esteban
Journal:  Infect Drug Resist       Date:  2010-11-23       Impact factor: 4.003

Review 9.  Hepatitis C virus NS3 inhibitors: current and future perspectives.

Authors:  Kazi Abdus Salam; Nobuyoshi Akimitsu
Journal:  Biomed Res Int       Date:  2013-10-27       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.